Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donzakimig PK and Safety in Healthy Chinese and Japanese Participants
NCT06716879Phase 1Completed
- Sponsor
- UCB
- Start
- Dec 2024
- Primary completion
- Apr 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of donzakimig in hidradenitis suppurativa (HS), sponsored by UCB. Primary endpoints: Treatment-Emergent Adverse Events at Day 57, Serious Treatment-Emergent Adverse Events at Day 57 and 3 more. Started Dec 2024; status: completed.
02
Drugs
donzakimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06716879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06716879.